Human tumors display a global reduction in miRNA expression[@R1],[@R2]. Inhibition of the miRNA processing pathway via knockdown of miRNA processing enzymes promotes cellular transformation and tumorigenesis; this effect can be attenuated by ectopic expression of let-7g, suggesting that inhibition of let-7 processing is likely to be central to promoting the transformed state[@R3]. Low levels of let-7 correlate with increased transformation capacity *in vitro*[@R3], and have been observed in various malignancies, including lung cancer,[@R9],[@R10] hepatocellular carcinoma[@R11], melanoma[@R12], and ovarian cancer[@R13]. Over-expression of let-7 represses cellular proliferation pathways, inhibits cell growth, and impairs tumor development in both xenograft models and in an autochthonous model of non-small cell lung cancer[@R3],[@R14],[@R15],[@R16]. Copy number loss[@R3],[@R17]--[@R19] and epigenetic silencing[@R20] of individual let-7 family members have been reported in human cancers, and such events have been suggested to contribute to the disease state. However, in tissues where let-7 family members are co-expressed, inactivation of individual let-7 miRNAs would be expected to only modestly decrease let-7 dosage, given the functional redundancy among family members. Therefore, we hypothesized that activation of *LIN28/LIN28B* could serve as a physiological mechanism by which levels of all let-7 family miRNAs are coordinately repressed in the context of human malignancy.

We initially sought to determine whether over-expression of Lin28 could promote cellular transformation in experimental settings. We observed that over-expression of Lin28 in NIH/3T3 cells potently depletes levels of multiple mature let-7 family member miRNAs ([Fig. 1a](#F1){ref-type="fig"}), leading to a concomitant increase in protein levels of c-Myc, a let-7 target ([Fig. 1b](#F1){ref-type="fig"}). NIH/3T3 cells overexpressing Lin28 formed colonies in soft agar ([Fig 1c--d](#F1){ref-type="fig"}) at a frequency comparable to BCR-ABL ([Fig. S1](#SD1){ref-type="supplementary-material"}) and slightly lower than that reported for c-Myc (1--2%), both of which are weakly transforming in this assay[@R21]. Expression of Lin28 together with BCR-ABL resulted in an increase in both colony size and number as compared with either Lin28 or BCR-ABL alone ([Fig. S1](#SD1){ref-type="supplementary-material"}). NIH/3T3 cells expressing either Lin28 or LIN28B formed tumors in nude mice ([Fig. S1b](#SD1){ref-type="supplementary-material"} and [Table S1](#SD1){ref-type="supplementary-material"}). Although the tumors were small and of delayed latency, they displayed evidence of local invasion ([Fig. S1b](#SD1){ref-type="supplementary-material"}), similar to what has been observed upon global inhibition of miRNA processing[@R3], and consistent with a recent report that Lin28 enhances metastasis[@R22]. Co-expression of Lin28 and 7S21L (a let-7 loop mutant capable of being processed to mature let-7 in the presence of Lin28[@R23]) abrogated the ability to form colonies in semisolid medium ([Fig 1c--d](#F1){ref-type="fig"}); thus, Lin28 transforms NIH/3T3 cells via the de-repression of let-7 target genes. We also observed that Lin28 over-expression enhanced transformation of a mouse lung adenocarcinoma cell line in which impairment of miRNA processing had been previously reported to be transforming[@R3] ([Fig. S2](#SD1){ref-type="supplementary-material"}).

We next tested Lin28 for its ability to transform cytokine-dependent BaF/3 cells to factor independence. Over-expression of Lin28 in BaF/3 cells potently depleted mature let-7 family members and led to the upregulation of the let-7 targets K-Ras and c-Myc ([Fig. 1e--f](#F1){ref-type="fig"}). Co-expression of Lin28 and a weakly transforming variant of c-SRC (SRC/Y530F) conferred factor independence upon Ba/F3 cells ([Fig. 1g--h](#F1){ref-type="fig"}) and strongly promoted growth in semisolid medium ([Fig. 1i](#F1){ref-type="fig"}). Mice injected with Ba/F3 cells co-expressing Lin28 and Src/Y530F succumbed to leukemic disease more rapidly than mice injected with Ba/F3 cells expressing Src/Y530F alone ([Fig. 1j](#F1){ref-type="fig"}). Lin28 cooperated similarly with a weakly transforming variant of c-Abl (Abl/G2A) to transform Ba/F3 cells ([Fig. 1k--m](#F1){ref-type="fig"}). Notably, BCR-ABL, v-abl, and v-src have all been suggested to transform lymphoid cells via a similar pathway[@R24]. Together, these experiments demonstrate that over-expression of Lin28 facilitates cellular transformation in multiple *in vitro* assays and accelerates disease progression in a murine model.

To determine whether *LIN28* and *LIN28B* are aberrantly expressed in the setting of human cancer, we examined *LIN28* expression by microarray analysis of a large panel of human cancer cell lines; we observed expression in 3.2% of cell lines (17/527; [Fig. S3a](#SD1){ref-type="supplementary-material"}), including lines derived from germ cell tumors, Wilms' tumor (WT), and hepatocellular carcinomas (HCC). Analysis of microarray data available for the National Cancer Institute panel of 60 cell lines (NCI-60) revealed *LIN28* expression in 5% (3/60) and *LIN28B* expression in 10% (6/60) of the lines ([Fig. S3b](#SD1){ref-type="supplementary-material"} and [Table S2](#SD1){ref-type="supplementary-material"}). We also performed quantitative PCR analysis on a select panel of cancer cell lines and found several that express *LIN28B*, including multiple cell lines derived from patients in the blast crisis phase of chronic myeloid leukemia (CML) ([Table S2](#SD1){ref-type="supplementary-material"}). Examination of LIN28 expression in a range of primary tumor types by immunohistochemistry on a multi-tumor tissue microarray revealed that LIN28 was highly overexpressed in diverse tumor types including colon cancer, breast cancer, lung cancer, and cervical cancer ([Fig. S4](#SD1){ref-type="supplementary-material"} and [Table S3](#SD1){ref-type="supplementary-material"}). Together, these data show that *LIN28*/*LIN28B* are aberrantly expressed in ∼15% of surveyed cancer samples.

We surmised that activation of *LIN28*/*LIN28B* could represent a physiologic means by which let-7 levels are coordinately repressed in a subset of human cancers, and that over-expression of these factors might modify disease severity. Given that we observed over-expression in cell lines from patients with CML, we examined levels of *LIN28* and *LIN28B* in peripheral blood from patients in either chronic phase (CP) or blast crisis (BC) of CML. *LIN28* expression was detected more frequently in patients with BC-CML (42.8%, 6/14) or accelerated phase CML (40%, 4/10) than in patients with CP-CML (9.1%, 1/11) ([Fig. 2a](#F2){ref-type="fig"}). Furthermore, analysis of 13 paired CP-BC samples showed activation of *LIN28B* upon progression to BC in three patients (23%, 3/13) ([Table S4](#SD1){ref-type="supplementary-material"}). Therefore *LIN28*/*LIN28B* expression is associated with disease progression in a subset of CML patients. Interestingly, we observed that expression of HMGA2, a let-7 target gene, shows a similar relationship with disease progression in CML, as has also been reported elsewhere[@R25] ([Fig. S5](#SD1){ref-type="supplementary-material"}). This supports the notion that *LIN28*/*LIN28B* activation drives progression in CML via let-7 pathways. To determine whether cell lines derived from patients with BC-CML might be dependent on *LIN28*/*LIN28B* for growth, we inhibited *LIN28B* expression in K562 cells by RNA interference. Infection of K562 cells with an shRNA against *LIN28B* restored levels of mature let-7 miRNAs ([Fig. 2b--c](#F2){ref-type="fig"}), decreased levels of c-MYC ([Fig. 2d](#F2){ref-type="fig"}), impaired proliferative capacity and the ability to form colonies in soft agar ([Fig. 2e--f](#F2){ref-type="fig"}), and resulted in morphological changes suggestive of differentiation ([Fig. 2g](#F2){ref-type="fig"})[@R26]. Similar results were obtained in a second CML-BC cell line and in a lung adenocarcinoma cell line ([Fig. S6](#SD1){ref-type="supplementary-material"}--[Fig. S7](#SD1){ref-type="supplementary-material"}), both of which express LIN28B.

We next sought to determine whether *LIN28*/*LIN28B* might be similarly associated with advanced disease in HCC. We performed genome-wide mRNA and microRNA profiling on 89 HCC samples. *LIN28B* was highly expressed in a subset of HCCs, and these tumors displayed coordinate repression of all let-7 family miRNAs ([Fig. 3a](#F3){ref-type="fig"}). Gene set enrichment analysis revealed that expression of let-7 target genes and myc target genes were significantly enriched in *LIN28B*-expressing tumors ([Fig. 3b](#F3){ref-type="fig"}), suggesting that *LIN28B* represses let-7 and functionally activates let-7 targets in the setting of HCC. Tumors with high *LIN28B* expression accumulated in a molecular subclass defined by a meta-analysis of published transcriptome datasets (YH and TRG, data not shown), which is characterized by high serum alpha-fetoprotein level, higher tumor grade, and c-MYC activation (p=0.006, Fisher's exact test). Consistently, *LIN28B* expression was observed in 66% (4/6) of tumors from patients with serum alpha-fetoprotein (AFP) \> 10,000 ng/ml as compared to 16.3% (15/92) (p=0.00981, Fisher's Exact Test). *LIN28B*-expressing tumors also fell predominantly within a subclass characterized by a proliferative nature as defined by unsupervised clustering[@R27] (p=0.004), and most *LIN28B*-expressing tumors were of advanced stage ([Fig. 3d](#F3){ref-type="fig"}). Moreover, *LIN28B* expression was associated with a significantly increased incidence of early recurrence (within 2 years of resection, p=0.02, log-rank test), but was not associated with late recurrence ([Fig. 3c](#F3){ref-type="fig"}). Early recurrence is an indicator of malignant disease while late recurrence is thought to occur as a de novo event from the carcinogenetic microenvironment of the cirrhotic liver[@R28]. Knockdown of *LIN28B* in HepG2 cells (an HCC cell line expressing *LIN28B*) led to a marked decrease in the number of colonies formed in semisolid medium ([Fig. 3e](#F3){ref-type="fig"}). Together, these results demonstrate that *LIN28B* is associated with advanced disease and poor clinical outcome in HCC.

To determine whether *LIN28*/*LIN28B* are associated with advanced malignancy in other settings, we interrogated published microarray data from multiple tumor types and found high levels of *LIN28* and/or *LIN28B* expression in a discrete subset of human tumors including WT ([Fig. S8](#SD1){ref-type="supplementary-material"}), ovarian carcinoma ([Fig. S9](#SD1){ref-type="supplementary-material"}), and germ cell tumors (West et al., submitted). Strikingly, *LIN28*/*LIN28B* expression was specifically associated with advanced disease in all of these tumor types. In WT, *LIN28*/*LIN28B* expression was only observed in Stage 3 or Stage 4 tumors (p= 0.00361, Fisher's exact test), but not in lower stage tumors ([Fig. S8](#SD1){ref-type="supplementary-material"}). Among ovarian carcinomas, *LIN28*/*LIN28B* expression was observed predominantly in tumors of histological Grade 2 or 3, rather than Grade 1 ([Fig. S9](#SD1){ref-type="supplementary-material"}).

Various mechanisms may explain *LIN28*/*LIN28B* expression in human cancers, including genomic amplification, aberrant hypomethylation, and expression in a rare cell of origin that acquires additional malignant lesions. Amplification of regions containing the *LIN28* (1p36) [@R29] and *LIN28B* (6q21) [@R30],[@R31] loci in human cancers have been reported. We surveyed SNP array data from 3330 primary tumors and cell lines to check for focal copy number changes at the *LIN28* and *LIN28B* loci. Although we observed no appreciable copy number changes at the *LIN28* locus, a small subset of cancers showed focal copy number increases of *LIN28B* (1.7% overall) ([Table S5](#SD1){ref-type="supplementary-material"} and [Figure S10](#SD1){ref-type="supplementary-material"}). However, most amplification events were rare and typically broad, involving both *LIN28B* and numerous neighboring genes. Analysis of SNP array data in 31 CML-BC samples (22 myeloid, 9 lymphoid) revealed no focal alterations at either the *LIN28* or *LIN28B* loci (data not shown). Thus, while genomic amplification may explain *LIN28B* expression in a small number of tumors, it is unlikely to be a dominant mechanism of activation. We also assessed methylation status at a CpG island located within the *LIN28B* locus, and observed relative hypomethylation in *LIN28B*-expressing cell lines ([Fig. S11](#SD1){ref-type="supplementary-material"}), suggesting that aberrant hypomethylation may poise the *LIN28B* locus for transcriptional activation in some tumors. Interestingly, this region of aberrant hypomethylation overlaps with a recently defined c-Myc binding site within the *LIN28B* locus[@R32]. This, together with our observation that *LIN28B*-expressing tumors cluster in a high-Myc expression subclass, suggests that Myc may transcriptionally activate *LIN28B* in some contexts.

Notably, there have been several reported cases of WT with a translocation involving 6q21[@R33]--[@R37], the band on which *LIN28B* is located. To determine whether these translocations may be associated with altered expression of *LIN28B*, we analyzed a case of sporadic WT with a previously described chromosomal translocation t(6;15)(q21;q21)[@R33],[@R38]. Previous mapping by FISH analysis had narrowed the 6q21 breakpoint in this case to a region intergenic to two 6q21 genes, *HACE1* and *LIN28B*, and had demonstrated that loss of *HACE1* expression in a cohort of WT cases[@R39] was associated with altered methylation of several CpG islands in the region, including CpG-29 directly adjacent to the *LIN28B* gene ([Fig S12a](#SD1){ref-type="supplementary-material"}). To further map the 6q21 breakpoint in this case, we performed Southern blot assay using probes from the intergenic region. A probe covering CpG-29 and flanking sequences lying ∼3--4 kb upstream of the *LIN28B* transcriptional start site demonstrated rearrangement using *PstI*-digested genomic DNA from the index WT case compared to matching normal kidney and other controls ([Figure S12a--c](#SD1){ref-type="supplementary-material"}). Moreover, quantitative RT-PCR showed dramatically increased expression of *LIN28B* in the index case compared to patient-matched normal kidney ([Figure S12d](#SD1){ref-type="supplementary-material"}). A second WT cause carrying a t(6;15) ([Fig. S12e](#SD1){ref-type="supplementary-material"}) also displayed dramatically increased expression of *LIN28B* in tumor sample compared with normal kidney ([Fig. S12f](#SD1){ref-type="supplementary-material"}). Therefore, *LIN28B* may be activated by translocation, although the frequency of such events remains to be determined.

Lin28 and Lin28b are expressed in various stem cell populations[@R8],[@R40],[@R41], although there is scarce expression in most terminally differentiated somatic tissues[@R42]. Although our data suggest that altered gene expression of *LIN28* or *LIN28B* can promote tumorigenesis and is associated with advanced malignancy, we cannot rule out the possibility that in some settings, *LIN28* or *LIN28B* may be endogenously expressed in a rare cell of origin that develops into an aggressive tumor. We have observed relatively strong LIN28 expression within cells of the normal ovarian surface epithelium, thought to be the cells of origin of epithelial ovarian cancer ([Fig. S9](#SD1){ref-type="supplementary-material"})[@R43]. Some poor-prognosis HCCs have also been suggested to arise from a primitive cell of origin that shares gene expression patterns with fetal hepatoblasts[@R44].

Recently, LIN28 was used together with OCT4, NANOG, and SOX2 to reprogram human somatic fibroblasts to pluripotency[@R45]. Over-expression of other stem cell factors, such as BMI1[@R46] and OCT4[@R47],[@R48], has been reported to promote oncogenesis by driving self-renewal and proliferation. Moreover, poorly differentiated, aggressive human tumors have recently been shown to have an embryonic stem cell-like gene expression signature[@R49]; other embryonic factors have also been reported to have roles in tumor progression[@R50],[@R51]. Our data add *LIN28*/*LIN28B* to a growing list of embryonic genes involved in oncogenesis, and suggest a mechanism whereby repression of let-7 by LIN28/LIN28B may help to confer self-renewal capacity on cancer stem cells[@R52]. Antagonizing LIN28 and/or LIN28B function in tumors that overexpress these genes may provide a means to reactivate the expression of let-7 family tumor suppressors, and may thus be therapeutically beneficial.

Methods {#S1}
=======

Cell Culture {#S2}
------------

Cell lines were originally obtained from ATCC and cultured under standard conditions. BaF3/AblG2A and Baf3/SrcY530F lines have been described elsewhere[@R54]. LKR cells were derived from a mouse adenocarcinoma[@R55] and were a kind gift of Carla Kim.

Antibodies {#S3}
----------

The following antibodies were used for immunoblotting: c-myc (Santa Cruz, sc-764), KRas (Santa Cruz, sc-30), Abl-K12 (Santa Cruz, sc-131), c-Src (Cell Signaling, \#2110). Anti-Lin28 (Proteintech group) was used for immunohistochemistry.

Cloning and Plasmid Construction {#S4}
--------------------------------

Mammalian Lin28 and *LIN28B* cDNA were subcloned into pBabe.Puro and pMSCV.Neo retroviral vectors. pMSCV.Neo.let-7g construct was previously described[@R3]. *LIN28B* shRNA in lentiviral plasmid was purchased from Sigma-Aldrich (TRCN0000122599). Control shRNA was commercially purchased (SHC002V, Sigma-Aldrich)

Immunohistochemistry {#S5}
--------------------

Sections of tissues were deparaffinized with xylene and rehydrated with graded series of ethanol (absolute, 95%, 80% and 50%, respectively, and distilled water), followed by two washes of 5 min each in PBS-T. Antigen retrieval was performed for 20 min in sodium citrate buffer (10mM pH 6) at 90--100°C followed by wash with PBST 1× 5 min. Tissue sections were then incubated for 10 min in 3% (v/v) hydrogen peroxide in methanol to block endogenous peroxidase activity. Sections were then washed for 5 min in PBS-T and blocked at room temperature for 1 h by using 2% normal goat serum, 2% bovine serum albumin (BSA) and 0.1% triton-X in PBS. Tissue sections were then incubated in humidified chamber for overnight incubation at 4°C with primary antibody (1/200 in TBST). Sections were subsequently washed with PBS-T (3× 5min) and incubated at room temperature for 1 h with secondary antibody (goat anti rabbit). After a wash with PBS-T (3× 5min), sections were incubated with ready to use streptavidin peroxidase (Lab Vision, Fremont, CA) for 10 min at room temperature and then color was developed by using a DAB kit (Vector laboratories, Burlingame, CA). Sections were counterstained with hematoxylin.

Viral Production {#S6}
----------------

For ecotropic viral production, retroviral plasmid DNA and pCL-Eco were transfected into 293T cells in a 1:1 mass ratio and virus harvested after 48h. For VSV-G pseudotyped lentivirus, viral plasmid, lentiviral gag/pol, and VSV-G were transfected in a mass ratio 1:0.9:0.1, and virus was harvested after 72 hrs. 1 mL of unconcentrated viral supernatant was used to infect 50,000 cells. Infected cells were selected on antibiotic prior to subsequent analysis.

Bisulfite Sequencing {#S7}
--------------------

Bisulfite sequencing was performed as described[@R56] with the commercially available EZ DNA Methylation Kit (Zymo Research). Primers were designed using MethPrimer to target a region 1 kb downstream of the *LIN28B* transcriptional start site.

Transformation and Growth Assays {#S8}
--------------------------------

Soft agar assays were performed essentially as described previously with 50,000 cells seeded per well[@R57]. Colonies were stained with 0.005% crystal violet and counted after 3--4 weeks of growth.

Quantitative RT-PCR {#S9}
-------------------

quantitative RT-PCR was used for detection of mature miRNA species as described previously[@R8]. mRNA expression analysis was performed by quantitative PCR using SYBR green dye with fold-changes calculated by the ΔΔC~t~ method or using *LIN28B* Taqman probe on patient samples.

Microarray Data Analysis {#S10}
------------------------

The following are Gene expression Omnibus accession numbers for publically available microarray datasets analyzed for *LIN28* and *LIN28B* expression in this paper: GSE11024, GSE6222, GSE9843, GSE9891, GSE4170. Log~2~ transformed expression data were normalized to the average expression signal for normal tissue (where available), or row-normalized for the GSE9843 and GSE9891 datasets. Cutoff for over-expression was taken as a normalized expression value of 2 or greater unless stated otherwise. For microarray profiling of cancer cell lines, the samples run were from the Sanger Cell line collection as described at <http://www.sanger.ac.uk/genetics/CGP/CellLines/> using an HT-HG_U133A chip, miRNAs were profiled using our previously described platform[@R58]. The HCC samples were stratified into LIN28B-high and -low groups based on a cut-off of 200U. LIN28B amplification status was determined in a panel of 1,103 cancer DNA samples -- consisting of breast cancer (n = 242), chronic myelogenous leukemia (n = 6), lung non-small cell cancer (n=734), and hepatocellular carcinoma (n=121) -- hybridized to the Affymetrix 250K StyI SNP Array (Beroukhim et al, Manuscript in preparation). Copy number estimates for LIN28B were normalized using a panel of population-matched controls and segmented using the Gain and Loss of DNA (GLAD) algorithm[@R59].

Human tissue samples {#S11}
--------------------

The expression levels of let-7 species and *LIN28B* were assessed in 89 HCV-related hepatocellular carcinoma (HCC) samples including 77 clinically early HCC (25 pathologically early and 52 pathologically advanced cases) and 12 very advanced cases. All the samples were obtained from patients undergoing liver resection in the three hospitals of the HCC Genomic Consortium: Mount Sinai School of Medicine, NY (US), Hospital Clinic, Barcelona (Spain) and Istituto Nazionale dei Tumori, Milan (Italy). We obtained approval from the Institutional Review Board and patients were properly consented.

Quantitative PCR detection of *LIN28* and *LIN28B* on CML samples {#S12}
-----------------------------------------------------------------

Total RNA was isolated from cell lines and patient samples (a mixture of both peripheral blood and bone marrow) using Trizol reagent (Invitrogen; Carlsbad, CA). cDNA was generated from 1mg of total RNA using Cloned AMV Reverse Transcriptase (Invitrogen). The cDNA synthesis was performed under the following thermocycler conditions: 25°C for 10 minutes, 42°C for 60 minutes, 99°C for 5 minutes and 4°C hold. Gene specific primers and probes were designed using Primer Express Version 3 (ABI; Foster City, CA). All of the QPCR primers and florescent probes were manufactured by Integrated DNA Technologies (Coralville, IA). Real-time quantitative PCR (QPCR) was performed on 100ng of synthesized cDNA in a 50ml reaction using the ABI 7900HT Real-Time PCR System under the following conditions: stage 1, 95°C for 10 minutes: and stage 2, 95°C for 15 seconds, 60°C for 1 minute for a total of 40 cycles.

Fluorescence in-situ hybridization (FISH) {#S13}
-----------------------------------------

FISH was performed using standard protocols on metaphase nuclei as previously described.[@R1] The RP-770C15 and RP-809N15 BAC probes were obtained from the RPCI-11 human BAC library and directly labelled with SpectrumGreen and SpectrumRed, respectively, via a nick translation kit (Vysis), hybridized in a humidified chamber overnight at 37°C, and counterstained with DAPI. Detection was performed using a Zeiss Axioplan epifluorescence microscope equipped with a COHU-CCD camera and Quips software.

Supplementary Material {#SM}
======================
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![Lin28 Transforms NIH/3T3 cells\
**(A)** Levels of mature miR species in representative infection determined by quantitative PCR in NIH/3T3 cells infected with pMSCV.Neo or pMSCV.Neo.Lin28, and selected on G418. **(B)** Western blot analysis of extracts from NIH/3T3 cells infected with MSCV.Neo/pBabe.Puro, pMSCV.Neo.Lin28/pBabe.Puro, or pMSCV.Neo.Lin28/pBabe.Puro.7S21L, selected with Puromycin and G418. **(C)** Levels of mature let-7g in NIH/3T3 cells infected with MSCV.Neo/pBabe.Puro,pMSCV.Neo.Lin28/pBabe.Puro, or pMSCV.Neo.Lin28/pBabe.Puro.7S21L, selected with Puromycin and G418. **(D)** Colony numbers in semisolid media for 25,000 NIH/3T3 cells infected with pMSCV.Neo/pBabe.Puro, pMSCV.Neo.Lin28/pBabe.Puro, or pMSCV.Neo.Lin28/pBabe.Puro.7S21L, selected with Puromycin and G418. Colonies were counted after 4 weeks with five random fields counted per well. Results are plotted as average colony number +/− S.E.M., N=3. **(E)** Western blot analysis on cell extracts from Ba/F3 cells infected with pMSCV.Neo and pMSCV.Neo.Lin28, selected on G418. **(F)** Levels of mature miR species in representative infection determined by quantitative PCR in Ba/F3 cells infected with pMSCV.Neo or pMSCV.Neo.Lin28, and selected on G418. **(G)** Western blot analysis on cell extracts from Ba/F3 cells infected with pEYK.Puro.SrcY530F and either pMSCV.Neo or pMSCV.Neo.Lin28 and selected on puromycin and G418 **(H)** Ba/F3 lines established in (C) were plated in media without IL-3 at 10,000 cells per well. Cells were stained with Trypan blue and viable cells were counted 6d after plating. **(I)** Colony formation of Ba/F3 cells expressing Src/Y530F or Src/Y530F + Lin28 in semisolid medium, plated at 50,000 cells per well in medium without IL-3. Quantitation of colony number from soft agar assay after 21d of growth. Results are plotted as average colony number per well +/− S.E.M., N=3. **(J)** Survival of immunocompromised mice injected with 10^7^ Ba/F3 cells expressing Src-Y530F or Src-Y530F+Lin28. Average survival time 51.4d vs. 33.2d vs. respectively, p=0.00276 **(K)** Western blot analysis of extracts from Ba/F3 cells infected with pBabe.Puro or pBabe.Puro.Lin-28, selected on Puromycin. **(L)** Ba/F3 lines established in (C) were plated in media without IL-3 at 10,000 cells per well. Cells were stained with Trypan blue and counted 3d after plating. **(M)** Quantitation of colony number from soft agar assay. Results are plotted as average colony number per well +/− S.E.M., N=3. \*, p\<0.05; \*\*, p\<0.01.](nihms115931f1){#F1}

![*LIN28B* Knockdown Impairs Growth and Triggers Differentiation of K562 Cells\
**(A)** Lin28 expression as determined by quantitative PCR in peripheral blood from patients in either chronic phase, accelerated phase, or myeloid blast crisis. **(B)** Levels of *LIN28B* expression determined by quantitative PCR in K562 cells infected with pLKO.controlshRNA or pLKO.*LIN28B*shRNA, and selected on Puromycin. **(C)** Levels of mature miR species determined by quantitative PCR in K562 cells were infected with pLKO.controlshRNA or pLKO.*LIN28B*shRNA, and selected on Puromycin. **(D)** Western blot for K-Ras and c-Myc on cell extracts from K562 cells infected with pLKO.controlshRNA or pLKO.*LIN28B*shRNA and selected on Puromycin. **(E)** Cell proliferation of K562 cells infected with pLKO.controlshRNA or pLKO.*LIN28B*shRNA, selected on Puromycin, and seeded at 10000 cells per well. Results are plotted as average cell number per well +/− S.E.M. N=3. **(F)** Colony formation for K562 cells infected with pLKO.controlshRNA or pLKO.*LIN28B*shRNA and plated in semisolid medium. 5000 cells were plated per well and colonies were counted after 21d. **(G)** Wright-Giemsa stain on cytospin preparation of K562 cells infected with pLKO.controlshRNA or pLKO.*LIN28B*shRNA, selected on Puromycin. \*, p\<0.05; \*\*, p\<0.01.](nihms115931f2){#F2}

![*LIN28B* is associated with poor outcome in hepatocellular carcinoma\
**(A)** Expression of let-7 family miRNAs measured as part of genome-wide microRNA profile in 89 human HCC Tumor samples were ordered according by decreasing expression level of *LIN28B* as measured on an mRNA expression microarray on the same samples. **(B)** Induction of experimentally-defined MYC target gene signatures (left and middle) and let-7 target gene expression (right) was evaluated in *LIN28B*-high tumors using Gene Set Enrichment Analysis **(C)** *LIN28B*-high tumors showed significantly higher incidence of early recurrence (within 2 years after surgical treatment, p=0.02, log-rank test), but not late recurrence (p=0.22), as compared with *LIN28B*-low tumors. **(D)** The percentage of tumors expressing *LIN28B* is higher in BCLC-C stage HCC compared to BCLC-A or BCLC-B stage HCC. \[Barcelona Clinic Liver Cancer (BCLC) staging system: A:early, B : intermediate C: advanced, D: end --stage[@R53]\] **(E)** Serum AFP values were plotted against log2-normalized *LIN28B* expression values for patients with log2N signal \> 6.00. **(F)** Colony formation for HepG2 cells infected with pLKO.controlshRNA or pLKO.*LIN28B*shRNA and plated in semisolid medium. 50,000 cells were plated per well and colonies were counted after 14d. \*, p\<0.05; \*\*, p\<0.01.](nihms115931f3){#F3}
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